Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Progress in Lung Cancer Across Daiichi Sankyo’s DXd ADC Portfolio Updated DATROWAY® (datopotamab deruxtecan) combination data across three early-phase trials will be highlighted in patients ...

Daiichi Sankyo research and development global head Ken Takeshita said: “While we are disappointed with the OS results of HERTHENA-Lung02, we are conducting further biomarker analyses to better ...

“This year’s ASCO marks the fourth in a row where potential practice-changing ENHERTU data will be showcased,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “With the results ...

(RTTNews) - The Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan, co-developed by Merck & Co Inc. (MRK) and Daiichi ... said Ken Takeshita, Global Head ...

Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...

“EGFR-mutated non-small cell lung cancer has proven to be difficult-to-treat in the second-line metastatic setting and beyond,” said Ken Takeshita, MD, global head, R&D, Daiichi Sankyo. “While we are ...

Ken Takeshita, global head, R&D, Daiichi Sankyo, said: “Enhertu continues to transform the treatment of metastatic breast cancer with the first new data in more than a decade to demonstrate improved ...

(MRK) and Daiichi Sankyo on Thursday said that the companies have withdrawn their application to the U.S. Food and Drug ...

When Merck & Co. and Daiichi Sankyo last year received an FDA complete ... multiple clinical trials across 15 types of cancer," Ken Takeshita, M.D., Daiichi's global head of R&D, said in a statement.

Daiichi Sankyo's head of global R&D, Ken Takeshita, said that EGFR-mutated NSCLC is known to be difficult to treat in the second-line metastatic setting, but added that the company is "conducting ...

Daiichi Sankyo and MSD have voluntarily withdrawn the biologics licence application (BLA) in the US for their HER3-directed ...